REPLIMUNE GROUP, INC. Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
REPLIMUNE GROUP, INC. (REPL) reported Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest of -$80.87 million for the 12-month period ending 2021-03-31, per its 10-K filed 2021-05-20.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments · last filed 2021-05-20
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before equity method investments, income taxes, noncontrolling interest for fiscal 2021 was -$80.87M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before equity method investments, income taxes, noncontrolling interest for fiscal 2020 was -$52.63M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before equity method investments, income taxes, noncontrolling interest for fiscal 2019 was -$30.83M.
- REPLIMUNE GROUP, INC. income (loss) from continuing operations before equity method investments, income taxes, noncontrolling interest for fiscal 2018 was -$19.70M.
| Period end | Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest 12 month |
|---|---|
| 2021-03-31 | -$80.87M 10-K · filed 2021-05-20 |
| 2020-03-31 | -$52.63M 10-K · filed 2021-05-20 |
| 2019-03-31 | -$30.83M 10-K · filed 2020-06-03 |
| 2018-03-31 | -$19.70M 10-K · filed 2020-06-03 |
| 2017-03-31 | -$7.70M 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |